Big decision coming on Malvern pharma firm's non-opioid pain reliever

The Food and Drug Administration is expected to make a decision early next week on Recro Pharma's second attempt to get approval for its experimental non-opioid pain medicine. Last May, the FDA rejected the Malvern specialty pharmaceutical company's new drug application for intravenous meloxicam. Recro is seeking approval of IV meloxicam for the management of moderate-to-severe pain. An oral version of meloxicam is already marketed by Boehringer Ingelheim, under the brand name Mobic, to treat…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news